Embolization and Postinfarction Nephrectomy in Patients with
Primary Metastatic Renal Adenocarcinoma

Kh, Kurth; Fm, Debruyne; Rr, Hall; Denis, L.; Verbaes, A; Bollack, C; Hj, de Voogt; M, De Pauw; Silvester, R

doi:10.1159/000472789

Cited by 13 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Von verschiedenen Autoren wurde die Hypothese aufgestellt, daß durch die nach der Embolisation auftretende Tumornekrose eine effektive Immunantwort des Körpers auf Metastasen hervorgerufen wird (7,9,17). In der Tat fanden Kurth et al 1987 in einer Phase-II-Studie der EORTC-Gruppe eine deutliche Zunahme der zellulären Immunabwehr mit einem Maximum 48 Stunden nach Embolisation (8). Eine Verbesserung der Überlebenszeit konnte jedoch -ebenso wie bei anderen Autoren -nicht nachgewiesen werden (4,6).…”

Section: Materials Und Methodenunclassified

See 1 more Smart Citation

Prognostische Bedeutung des Vena-cava-Befalles bei Nierenzellkarzinom und Stellenwert der präoperativen Tumorembolisation

Wawersig¹,

Staehler²,

Pomer³

et al. 1993

Aktuel Urol

View full text Add to dashboard Cite

Section: Materials Und Methodenunclassified

“…Man erhoffte sich insbesondere bei Lungenmetastasen eine Remission oder eine verzögerte Progression der Krankheit (2,9,16). Erste Ergebnisse, die für diese Annahme sprachen, werden jedoch zunehmend widerlegt (6,8).…”

Section: Bei Dieser Untersuchung Des Vorliegendenunclassified

Prognostische Bedeutung des Vena-cava-Befalles bei Nierenzellkarzinom und Stellenwert der präoperativen Tumorembolisation

Wawersig¹,

Staehler²,

Pomer³

et al. 1993

Aktuel Urol

View full text Add to dashboard Cite

“…The complication rate is up to four times higher for palliative than pre-operative procedures [ 67 ]. Mortality related to the procedure ranges from 0% [ 56 ] to 5.8% [ 68 ]. Radical nephrectomy has a complication rate of 20% and mortality of 2% [ 69 ].…”

Section: Renal Cell Carcinomamentioning

confidence: 99%

Embolisation of cancer: what is the evidence?

Goode

Matson²

2004

Cancer Imaging

View full text Add to dashboard Cite

Embolisation has become an accepted modality of cancer treatment in patients with a variety of clinical scenarios. It is commonly used in clinical practice in the treatment of hepatocellular carcinoma, hepatic metastases from colorectal cancer and neuroendocrine tumours, and renal cell carcinoma. This review summarizes the current evidence for the efficacy of embolotherapy in these clinical settings, together with the associated complications.

show abstract

“…Kurth and coworkers [28] initiated a phase-II study, whereby 34 patients with metastatic renal cell carcinoma were treated by angio-infarction and delayed nephrectomy; the mortality was 5.8°70. Only one patient showed a complete remission, but 80% showed progression within 6 months of nephrectomy.…”

Section: Angio-infarctionmentioning

confidence: 99%

Adjuvant therapy in renal cancer

Goepel¹,

Rübben²

1991

World J Urol

View full text Add to dashboard Cite

Surgery is the therapy of choice for patients with local renal cancer, but the results are unsatisfactory if the disease is locally advanced or systemic disease is present. As for the stage-related prognosis, patients with local disease (T1-2 NO M0) show good prognosis, with a 5-year survival of 90-100% after nephrectomy. In these patients the indication for adjuvant treatment is limited; it is almost impossible to document the statistically significant efficacy for adjuvant treatment, even when this therapy results in a long-term complete remission rate of more than 50% of the patients with metastatic disease. If such a drug were available, survival would be improved by 5%, but more than 1200 patients would have to be included in this protocol to reveal any significance. Patients with locally advanced disease (T3-4) or with nodal or distant metastases (N1-3, M1) have a worse prognosis, even if the tumor can be completely removed surgically; the 5-year survival rates are 60%, 25% and 5%, respectively. For these patients it is reasonable to start prospective statistical studies concerning adjuvant treatment after surgery. The aims of the investigations should be survival, local or systemic progression of the disease, and quality of life. However, the number of prospective trials is still limited and the results are disappointing: hormone therapy, chemotherapy, immunotherapy and radiotherapy in metastatic renal cancer have reached response rates above 30%; a complete response has been seen in less than 10% of all cases and only for a short period of time. Therefore, we do not recommend any kind of adjuvant treatment after radical nephrectomy. Even adjuvant surgery (complete lymph-node dissection) cannot be recommended as a routine procedure, until the benefit for the patients has been proven by prospective trials.Adjuvant therapy is an additional treatment applied after complete removal of all detectable tumor by induction

show abstract

Embolization and Postinfarction Nephrectomy in Patients with Primary Metastatic Renal Adenocarcinoma

Cited by 13 publications

References 16 publications

Prognostische Bedeutung des Vena-cava-Befalles bei Nierenzellkarzinom und Stellenwert der präoperativen Tumorembolisation

Prognostische Bedeutung des Vena-cava-Befalles bei Nierenzellkarzinom und Stellenwert der präoperativen Tumorembolisation

Embolisation of cancer: what is the evidence?

Adjuvant therapy in renal cancer

Contact Info

Product

Resources

About